30.06.2022 | 31.03.202

1.624.19

Audited

39,852.7 3,535.5 2,443.4 2,511.15 4,872.58

15.162.0

39,653.1 3,591.8

2,500.88 2,454.72

Unaudited

30.06.2022

Unaudited

FOR THE QUARTER ENDED 30/06/2023 (Rs In					
Ī.,		Q	uarter ende	ed	Year Ended
SI.		30-06-2023	31-03-2023	30-06-2022	31-03-2023
10.		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from operations (net)	78.47	77.889	6.98	382.29
2	Net Profit / (Loss) for the period				
	(before Tax, Exceptional and / or				
	Extraordinary Items)	18.87	31.56	-12.80	98.37
3	Net Profit / (Loss) for the period (before				
	Tax and after Exceptional and / or				
	Extraordinary Items)	18.87	31.56	-12.80	98.37
4	Net Profit / (Loss) for the period (after				
	Tax and after Exceptional and / or				
	Extraordinary Items)	18.87	16.30	-9.50	83.11
5	Total Comprehensive Income for the				
	period [Comprising Profit / (Loss) for the				
	period (after tax) and Other				
	Comprehensive Income (after tax)]	18.87	16.30	-9.50	83.11
6	Equity Share Capital	1240.00	1240.00	1240.00	1240.00
7	Earnings per Share (before extraordinary				
	items (of Rs.10/- each) for continued and				
ı	discontinued operations	10.00	10.00	10.00	10.00

NOTES:

Place : Chennai

Date: 14.08.2023

- The above results of the three months ended 30th June 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th August 2023.
- The Company operates only in only one business segment The Statutory Auditors of the company have carried out a review of the results for the quarter
- Ended 30.06.2023. In Compliance with the Ministry of Corporate Affairs (MCA) Notification dated 16th February. 2016, announcing the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), the Company has prepared its Standalone Financial Statements adopting Ind AS with effect 01st

April, 2017 with transition date of 01st April, 2016. BY ORDER OF THE BOARD For JMJ FINTECH LIMITED MANAGING DIRECTOR

ફાયનાન્સિયલ એક્સપ્રેસ

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2023

30.06.2023

Unaudited

30.06.2023 Unaudited

The above is an extract of the detailed format of unaudited Standalone and Consolidated results for the quarter ended on 30 June 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations

2015. The full format of unaudited Standalone and Consolidated results for the quarter ended on 30 June, 2023 are available on the

meetings held on 14th August, 2023. There are no qualifications in the limited review report issued for the quarter ended 30 June, 2023.

The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective

websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and the Company's website (www.zimlab.in).

6.700.7

(22.26) (14.30) (25.84)

18.54 22.66

4.872.58

Unaudited

994.41 723.64

Quarter Ended | Quarter Ended | Quarter Ended | Year Ended

10,444.85

990.15 713.97 664.39

Registered Office : Sadoday Gyan (Ground Floor) Opp. NADT, Nelson Square, Nagpur - 440 013, Maharashtra, India. Telephone No: Registered Office: 0712-2981960, Works Office: 07118-271990

for the Quarter ended June 30, 2023 (Rs. in Lak						
Particulars	Quarter ended 30.06.2023	Quarter ended 31.03.2023	Quarter ended 30.06.2022	Year ended 31.03.2023		
	Unaudited	Audited	Unaudited	Audited		
Total Income	18,503.16	18,272.93	15,119.78	67,503.42		
Net Profit / (Loss) for the period (before Tax,						
Exceptional and/ or Extraordinary Items)	3,288.01	2,987.03	2,297.96	10,543.82		
Net Profit/ (Loss) for the period before tax						
after Exceptional and/ or Extraordinary Items)	3,288.01	2,987.03	2,297.96	10,543.82		
Net Profit/ (Loss) for the period after tax						
after Exceptional and /or Extraordinary Items)	2,515.35	2,498.89	1,780.46	8,197.76		
Total Comprehensive Income for the period (Comprising Profit/ (Loss)						
or the period (after tax) and Other Comprehensive Income (after tax)	336.60	298.98	(383.40)	848.94		
Equity Share capital	1 ,004.12	1 ,003.65	1,000.65	1 ,003.65		
Earnings Per Share (of Re. 1/- each)						
for continuing and discontinued operations)-						
a) Basic (Rs.)	2 .51	2 .49	1 .78	8.18		
b) Diluted (Rs.)	2 .29	2 .29	1 .64	7.53		
Notes :						
1.Key Standalone financial information						
Turnover	6,010.41	5,684.51	4,787.80	21,756.23		
Profit/(Loss) before tax	1,059.62	796.44	539.62	3,452.75		
Profit/(Loss) after tax	843.82	665.66	397.60	2,784.85		

Phone: +91-44-24543500, CIN: L72200TN199PLC054429 | Email: investorqueries@saksoft.co.in | website: www.saksoft.com

2.The above is an extract of the detailed format of the Financial results for the quarter ended June 30, 2023 filed with the Stock Exchanges on August 14, 2023 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results are available on the Company's Website, www.saksoft.com and on the website of the Stock s www.nseindia.com and www.bseindia.com

3. Three Sixty Logica Testing Services Private Limited and Saksoft Inc, wholly owned subsidiaries of Saksoft Limited have acquired the entire shareholding of Solveda Software India Private Limited and Solveda LLC effective 11 August 2023, making these companies step down subsidiaries of Saksoft Limited

For and on behalf of the Board of Directors Aditya Krishna Place: Chennai Chairman & Managing Director Date: August 14, 2023

ZIM LABORATORIES LIMITED

Total Income from Operation Net Profit / (Loss) for the period before tax Net Profit / (Loss) for the period after tax

Profit / (Loss) before Tax Profit / (Loss) after Tax

Total comprehensive income

Total Comprehensive Income for the period

Other Equity (excluding Revaluation Reserve)
Earnings per share (not annualised)

Paid-up Equity Share Capital (Face value Rs. 10 per share)

CIN: L99999MH1984PLC032172, Website: www.zimlab.in

Particulars

Particulars

Notes: 1. Key Standalone financial Information of the company is given

CROP LIFE SCIENCE LIMITED

CIN: U24124GJ2006PLC048297 Incorporated on May 24, 2006 at Ahmedabad

Our Company was incorporated as Crop Life Science Limited under the provision of the Companies Act, 1956 vide certificate of incorporation dated May 24, 2006 issued by the Asstt. Registrar of Companies, Ahmedabad and Certificate of Commencement of Business dated July 6, 2006 issued by Registrar of Companies, Ahmedabad. The Corporate Identification Number of our Company is U24124GJ2006PLC048297. For further Details of Incorporation and Change in Registered Office of our Company, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page No. 128 of the Prospectus.

Registered office: 209, "Primate", Near Judges Bunglow Cross Road, Bodakdev, Ahmedabad – 380015, Gujarat, India.

Tel No.: 079-40373967; Website: www.croplifescience.com; E-Mail: cs@croplifescience.com; Contact Person: Sherry Kallii Sunny, Company Secretary and Compliance Officer

PROMOTER OF THE COMPANY: RAJESH LUNAGARIYA AND ASHVINKUMAR LUNAGARIA

THE ISSUE

INITIAL PUBLIC ISSUE OF 51,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CROP LIFE SCIENCE LIMITED ("CLSL" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 52 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹42 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹2672.80 LAKHS ("THE ISSUE"), OF WHICH 2,60,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASHATA PRICE OF ₹ 52 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 42 PER EQUITY SHARE AGGREGATING TO ₹ 135.20 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e., NET ISSUE OF 48,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 52 PER EQUITY SHARE AGGREGATING TO ₹ 2537.60 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 29.99% AND 28.47% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO. 237 OF THE PROSPECTUS.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE ISSUE PRICE IS 5.2 TIMES OF THE FACE VALUE

THIS ISSUE IS BEING MADE IN TERMS OF REGULATION 229(2) OF CHAPTER IX OF THE SECURITIES EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED ("SEBI ICDR REGULATIONS"). IN TERMS OF RULE 19(2)(b)(i) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED, THIS IS AN ISSUE FOR AT LEAST 25% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THIS ISSUE IS BEING MADE THROUGH A FIXED PRICE ISSUE AND ALLOCATION IN THE NET ISSUE TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 253 OF THE SEBI ICDR REGULATIONS 2018. FOR FURTHER DETAILS, PLEASE REFER CHAPTER TITLED "ISSUE PROCEDURE" BEGINNING ON PAGE 246 OF THE PROSPECTUS.

FIXED PRICE ISSUE AT ₹ 52/- PER EQUITY SHARE

MINIMUM APPLICATION SIZE OF 2,000 EQUITY SHARES AND IN MULTIPLES OF 2,000 EQUITY SHARES THEREAFTER

ISSUE **PROGRAMME**

ISSUE OPENS ON: FRIDAY, AUGUST 18, 2023

ISSUE CLOSES ON: TUESDAY, AUGUST 22, 2023

CREDIT RATING: As this is an Issue of Equity there is no credit rating for this Issue.

section "Material Contracts and Documents for Inspection" on page 307 of the Prospectus.

subscribed 2500 Equity Shares each respectively of ₹ 10/- each aggregating to 10,000 Equity Shares.

LIABILITY OF MEMBERS: The Liability of members of Company is Limited.

Company see "Capital Structure" on page 54 of the Prospectus.

ASBA* Simple, Safe, Smart way of Application - Make use of it!!!

*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details check section on ASBA below.

Mandatory in Public Issues from January 01, 2016. No cheque will be accepted..

For details on the ASBA and UPI process, please refer to the details given in Application Form and abridged prospectus and also please refer to the section RISK IN RELATION TO THE FIRST ISSUE: This being the first Public Issue of our Company, there has been no formal market for the securities of our issue Procedure" beginning on page 246 of the Prospectus. The process is also available on the website of Association of Investment Bankers of India Company. The face value of the shares is ₹10 per Equity Shares and the Issue price is ₹52 per Equity Shares, which is 5.2 times of the face value. The ("AIBI"), the website of National Stock Exchange of India Limited ("NSE") and in the General Information Document. ASBA Application forms can be issue Price (as determined by our Company in consultation with the Lead Manager) as stated in the chapter titled on "Basis for Issue Price" beginning on downloaded from the website of the National Stock Exchange of India Limited ("NSE") and can be obtained from the list of banks that is available on the page no. 71 of the Prospectus should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in.

IN TERMS OF THE CIRCULAR NO. CIR/CFD/POLICYCELL/11/2015 DATED NOVEMBER 10, 2015 AND ALL POTENTIAL INVESTORS after listing. PARTICIPATE IN THE ISSUE ONLY THROUGH APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA) PROCESS PROVIDING DETAILS GENERAL RISKS: Investments in equity-related securities involve a degree of risk and investors should not invest any funds in this Issue ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS (SCSB's) FOR THE SAME. FURTHER unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision pursuant TO CIRCULAR BEARING NO. SEBI/HO/CFD/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019 FOR IMPLEMETION OF PHASE II FOR UPI in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019. ALL POTENTIAL BIDDERS (EXCEPT ANCHOR INVESTORS) ARE REQUIRED TO The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA) PROCESS PROVIDING DETAILS OF THEIR Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section titled "Risk RESPECTIVE ASBA ACCOUNT OR UPI ID (IN CASE OF RIIs), IN WHICH THE CORRESPONDING APPLICATION AMOUNTS WILL BE BLOCKED Factors" beginning on page no.23 of the Prospectus. BY THE SCSBs OR UNDER THE UPI MECHÀNISM, AS APPLICABLE.

BY THE SCSBs OR UNDER THE UPI MECHANISM, AS APPLICABLE.

BASIS OF ISSUE PRICE: The Issue Price is determined by the Company in consultation with the Lead Manager. The financial data presented in chapter FOR MORE DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO THE "ISSUE PROCEDURE" ON PAGE NO. 246 OF THE "Basis for Issue Price" on page 71 of the Prospectus is based on Company's Restated Consolidated Financial Statements. Investors should also refer to PROSPECTUS. IN CASE OF DELAY, IF ANY IN UNBLOCKING/ REFUND THE FUND, OUR COMPANY SHALL PAY THE INTEREST ON THE the chapter titled "Risk Factors" and "Restated Financial Information" on page 23 and 145 respectively of the Prospectus APPLICATION MONEY AT THE RATE OF 15% PER ANNUM FOR THE PERIOD OF DELAY.

The Application Forms which do not have the details of the applicant's depository account including DP ID, PAN, UPI ID (in case of RIBs using the UPI DEBENTURE TRUSTEES: This is an issue of Equity shares; hence appointment of debenture trustees is not required. The Application Forms which do not have the declars of the application and the Application Form and mechanism) and Beneficiary Account Number shall be treated as incomplete and rejected. In case DP ID and PAN mentioned in the Application Form and IPO GRADING: Since the Issue is being made in terms of Chapter IX of SEBI (ICDR) Regulations, 2018, there is no requirement of appointing an IPO entered into the electronic system of the stock exchange, do not match with the DP ID, Client ID and PAN available in the depository database, the application is liable to be rejected. Applicants will not have the option of getting allotment of the Equity Shares in physical form. The Equity Shares on allotment shall be traded only in dematerialized segment of the Stock Exchange. LISTING: The Equity Shares offered through the Prospectus are proposed to be listed on the SME Platform of National Stock Exchange of India Limited

("NSE Emerge"). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. Our Company has received an In Principal Approval Letter dated July 18, 2023 from National Stock Exchange of India Limited (NSE) for using its name in this offer document for listing of our shares on the SME NSE Emerge of National Stock Exchange of India Limited. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited ("NSE"). DISCLAIMER CLAUSE OF SEBI: Since the Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations, 2018, the Draft Prospectus was not

filed with SEBI and SEBI has not issued any observation on Offer Document. Hence, there is no such specific disclaimer clause of SEBI. However investors may refer to the entire "Disclaimer Clause of SEBI" on page 230 of the Prospectus.

DISCLAIMER CLAUSE OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by NSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to "Disclaimer Clause of the SME Platform of NSE" on page 230 of the Prospectus.

Investor should read the Prospectus carefully, including the "Risk Factors" on page 23 of the Prospectus before making any investment decision.

All capitalised terms used herein and not specifically defined shall have the same meaning as prescribed to them in Prospectus dated August 9.2

LEAD MANAGER TO THE ISSUE

Address: 612, 6th Floor, Shree Balaji Heights, Kokilaben Vyas Marg,

Prospectus and also please refer to the chapter titled "Issue Procedure" on page 246 of the Prospectus.

INTERACTIVE FINANCIAL SERVICES LIMITED

Ellisbridge, Ahmedabad - 380 009, Gujarat, India

Tel No.: 079 46019796; (M) +91-9898055647

Investor Grievance Email: info@ifinservices.in Contact Person: Mr. Pradip Sandhir

Web Site: www.ifinservices.in

SEBI Reg. No.: INM000012856

Place: Gujarat

Email: mbd@ifinservices.in

All capitalised terms used herein and not specifically defined shall have the same meaning as prescribed to them in Prospectus dated August 9, 2023. REGISTRAR TO THE ISSUE

PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg, Lower Parel (East) Mumbai-400011, Maharashtra India Tel No: +91-022 2301 8261; Fax No.: +91-022-2301 2517

Website: www.purvashare.com E-Mail: support@purvashare.com Investor Grievance Email: support@purvashare.com Contact Person: Ms. Deepali Dhuri SEBI Reg. No.: INR000001112

Sherry Sunny

CROP LIFE SCIENCE LIMITED 209, "Primate", Near Judges Bunglow Cross Road, Bodakdev, Ahmedabad - 380015, Gujarat, India. Tel No: 079-40373967 E-mail: cs@croplifescience.com Website: www.croplifescience.com

For, CROP LIFE SCIENCE LIMITED

Designation: Company Secretary & Compliance Officer

Sherry Sunny

Investors can contact our Company Secretary and Compliance Officer, the Lead Manager or the Registrar to the Issue, in case of any pre-Issue or post-Issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and nonreceipt of funds by electronic mode etc.

COMPANY SECRETARY AND COMPLIANCE OFFICER

UPI - Now mandatory in ASBA for Retail Investors applying through Registered Brokers, DPs &

RTAs. Retail Investors also have the options to submit the application directly to the ASBA

Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors

are required to ensure that the Bank Account used for applying is linked to their PAN.

can be given regarding an active or sustained trading in the equity shares of our Company or regarding the price at which the Equity Shares will be traded

ADDITIONAL INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013: Main Objects as per MoA of our Company: For

information on the main objects of our Company, see "History and Certain Corporate Matters" on page 128 of the Prospectus and Clause III of the Memorandum of Association ("MoA") of our Company. The MoA is a material document for inspection in relation to the Issue. For further details, see the

CAPITAL STRUCTURE: Authorised Share Capital of ₹ 2500.00 Lakh divided into 2,50,00,000 Equity Shares of ₹10/- each. Pre-Issue issued, subscribed

& paid-up share capital is ₹ 1200.00 Lakh divided into 1,20,00,000 Equity Shares of ₹10/- each. For details of the share capital and capital structure of the

NAMES OF THE SIGNATORIES TO THE MOA OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Mr. Ashvin

Lunagaria, Mr. Rajesh Lunagariya, Mr. Tulsidas Lunagariya and Mr. Ramesh Talavia are the original subscribers to the Memorandum of Association who

AVAILABILITY OF PROSPECTUS: Investors should note that Investment in Equity Shares involves a degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus is available at the website of Stock Exchange dia.com, the website of Lead Manager at www.ifinservices.in, the website of our Company at www.croplifescience.com and the website of SEBI at www.sebi.gov.in.

AVAILABILITY OF APPLICATION FORMS: Application Forms can be obtained from the Registered Office of Company, and registered office of Lead Manager, Interactive Financial Services Limited. Application forms shall be available at selective location of Registered Brokers, Bankers to the Issue, RTA and Depository Participants. Application Forms can also be obtained from the National Stock Exchange of India Limited and the list of SCSBs is available on the websites of the National Stock Exchange of India Limited and SEBI.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): The investors are required to fill the application form and submit the same to the relevant SCSBs at the specific locations or registered brokers at the broker centers or RTA or DP's. The SCSB's will block the amount in the account as per the authority contained in application form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund. For more details on the ASBA process, please refer to the details given in application forms and

APPLICATION SUPPORTED WITH UNIFIED PAYMENTS INTERFACE: Investors are advised to carefully refer SEBI Circular (SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018 and as modified through its SEBI circular (SEBI/HO/CFD/DIL2/CIR/P/2019/50) dated April 3, 2019, SEBI circular (SEBI/HO/CFD/DIL2/CIR/P/2019/76) dated June 28, 2019, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2019/33 dated November 08, 2019, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2020/233 dated November 23, 2020, SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated June 02, 2021, for the procedure to be followed for applying through UPI. Retail Individual Investor have to apply through UPI Mechanism. Retail individual investor whose bank is not live on UPI as on date of this circular, may use the other alternate channels available to them viz. Submission of application form with SCSBs/ using the facility linked online trading, demat and bank account list. For further details, please refer the chapter titled "Issue Procedure" beginning on page 246 of the Prospectus.

BANKERS TO THE ISSUE AND REFUND BANKER AND SPONSOR BANK: ICICI Bank Limited. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated August 9, 2023.

CROP LIFE SCIENCE LIMITED is proposing, subject to market conditions and other considerations, public offer of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad, Gujarat on August 9, 2023. The Prospectus is available on the website of the Lead Manager at www.ifinservices.in, the website of the NSE i.e., www.nseindia.com and website of our Company at www.croplifescience.com.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Securities Act and applicable state securities laws in the United States. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

ver sensation l choose substance



The Indian Express.

nform your opinion with credible

ournalism